ATE68204T1 - Transformation von hefe des genus pichia. - Google Patents

Transformation von hefe des genus pichia.

Info

Publication number
ATE68204T1
ATE68204T1 AT85113733T AT85113733T ATE68204T1 AT E68204 T1 ATE68204 T1 AT E68204T1 AT 85113733 T AT85113733 T AT 85113733T AT 85113733 T AT85113733 T AT 85113733T AT E68204 T1 ATE68204 T1 AT E68204T1
Authority
AT
Austria
Prior art keywords
genus pichia
yeast
transformation
yeast strains
disclosed
Prior art date
Application number
AT85113733T
Other languages
English (en)
Inventor
David Womack Stroman
James Michael Cregg
George T Sperl
Michael Miller Harpold
Original Assignee
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co
Application granted granted Critical
Publication of ATE68204T1 publication Critical patent/ATE68204T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Enzymes And Modification Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Tires In General (AREA)
AT85113733T 1984-10-30 1985-10-29 Transformation von hefe des genus pichia. ATE68204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/666,579 US4879231A (en) 1984-10-30 1984-10-30 Transformation of yeasts of the genus pichia
EP85113733A EP0183070B1 (de) 1984-10-30 1985-10-29 Transformation von Hefe des Genus Pichia

Publications (1)

Publication Number Publication Date
ATE68204T1 true ATE68204T1 (de) 1991-10-15

Family

ID=24674609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85113733T ATE68204T1 (de) 1984-10-30 1985-10-29 Transformation von hefe des genus pichia.

Country Status (18)

Country Link
US (1) US4879231A (de)
EP (1) EP0183070B1 (de)
JP (1) JPH0681593B2 (de)
AT (1) ATE68204T1 (de)
AU (1) AU572353B2 (de)
CA (1) CA1297438C (de)
DE (1) DE3584353D1 (de)
DK (1) DK496485A (de)
ES (1) ES8609464A1 (de)
FI (1) FI94428C (de)
GR (1) GR852609B (de)
IE (1) IE58217B1 (de)
IL (1) IL76763A (de)
MX (1) MX430A (de)
NO (1) NO178975C (de)
PT (1) PT81402B (de)
SG (1) SG43092G (de)
ZA (1) ZA858180B (de)

Families Citing this family (470)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA872534B (en) * 1986-05-08 1987-11-25 Phillips Petroleum Co Yeast production of streptokinase
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL89989A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
US5204252A (en) * 1989-02-08 1993-04-20 Henkel Research Corporation Candida tropicalis transformation system
WO1990009434A1 (en) * 1989-02-13 1990-08-23 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of superoxide dismutase in pichia pastoris yeast cells
US5254466A (en) * 1989-11-06 1993-10-19 Henkel Research Corporation Site-specific modification of the candida tropicals genome
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992013951A1 (en) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
EP0578746B1 (de) * 1991-04-01 2002-07-03 Merck & Co., Inc. Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US5665600A (en) * 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
PT786257E (pt) 1992-06-03 2003-12-31 Genentech Inc Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
KR100342948B1 (ko) * 1993-03-03 2002-11-29 유니버시티 오브 아이오와 리써치 파운데이션 메틸로트로픽효모에서글리콜레이트산화효소의제조방법
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
ES2276396T3 (es) 1994-10-18 2007-06-16 Dendreon Corporation Proteinas anticoagulantes e inhibidores de la serina proteasa extraidos de nematodos.
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
US5955349A (en) * 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5965389A (en) * 1995-11-09 1999-10-12 Zymogenetics, Inc. Production of GAD65 in methylotrophic yeast
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
DE69734443T2 (de) 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US5736383A (en) * 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) * 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
MX9605082A (es) 1996-10-24 1998-04-30 Univ Autonoma De Nuevo Leon Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
AU729158B2 (en) 1997-01-31 2001-01-25 Genentech Inc. O-fucosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
CN101665536B (zh) 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1029046B1 (de) 1997-10-29 2008-09-24 Genentech, Inc. Durch wnt-1 induzierbare gene
IL135704A (en) 1997-10-29 2008-04-13 Genentech Inc Method of diagnosing neoplastic cell growth by detection of the wnt-1 induced secreted polypeptide wisp-1
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6316245B1 (en) * 1998-09-16 2001-11-13 Biongene Co., Ltd. Mutant cells of Pichia
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
EP1820859B9 (de) 1998-12-22 2009-10-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6720174B1 (en) 1999-01-28 2004-04-13 Novozymes A/S Phytases
EP1953173B1 (de) 1999-06-15 2009-11-18 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
WO2001029078A2 (en) * 1999-10-15 2001-04-26 Heska Corporation Method for production and use of mite group 1 proteins
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897943B1 (de) 1999-12-23 2011-12-14 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
WO2001077351A1 (en) * 2000-04-07 2001-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vectors and methods for dual protein expression in pichia pastoris and escherichia coli
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
WO2002000856A2 (en) 2000-06-30 2002-01-03 Flanders Interuniversity Institute For Biotechnology (Vib) Protein glycosylation modification in pichia pastoris
US7009045B2 (en) * 2000-07-14 2006-03-07 Archer-Daniels-Midland Company Transformation systems for flavinogenic yeast
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
JP4538192B2 (ja) 2001-05-01 2010-09-08 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫疾患を治療するための融合分子及び方法
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1992643A3 (de) 2001-06-20 2008-12-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
KR100942880B1 (ko) 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
EP2143438B1 (de) 2001-09-18 2011-07-13 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
NZ533933A (en) 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
AU2003243400B2 (en) 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7252933B2 (en) 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
EP2263691B1 (de) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Behandlung von Krebs mit dem rekombinanten, humanisierten, monoklonalen Anti-ERBB2-Antikörper 2C4 (rhuMAb 2C4)
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
EP1578373A4 (de) 2002-09-11 2007-10-24 Genentech Inc Neue zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322203A3 (de) 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
EP2364716A3 (de) 2002-11-08 2012-01-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen im Zusammenhang mit natürlichen Killerzellen
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
DE60335602D1 (de) * 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
ATE387494T1 (de) * 2002-12-20 2008-03-15 Hoffmann La Roche Hitzelabile desoxyribonuklease i-varianten
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
MXPA05009743A (es) 2003-03-12 2006-03-09 Genentech Inc Composiciones con actividad hematopoyetica e inmune.
EP1460425A1 (de) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Entglykosilierte Enzymen für Konjugaten
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
ES2424353T3 (es) 2003-07-08 2013-10-01 Genentech, Inc. Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7468267B2 (en) * 2003-08-25 2008-12-23 Funzyme Biotechnologies Sa Fungal proteins and nucleic acids encoding same
NZ596984A (en) 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
CA2486195C (en) * 2003-12-05 2012-03-06 Stephan Glaser Recombinantly expressed carboxypeptidase b and purification thereof
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
EP2305821A3 (de) 2004-02-13 2011-04-13 Novozymes A/S Proteasevarianten
US7858753B2 (en) 2004-03-30 2010-12-28 Glaxo Group Limited Immunoglobulins
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PT1771474E (pt) 2004-07-20 2010-05-03 Genentech Inc Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
AU2005304462B2 (en) 2004-11-10 2011-03-10 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7964195B2 (en) 2005-01-07 2011-06-21 Diadexus, Inc. Ovr110 antibody compositions and methods of use
RU2290434C1 (ru) * 2005-06-02 2006-12-27 Общество с ограниченной ответственностью "БиоГениус" Штамм дрожжей pichia pastoris 2-2 - продуцент тромбоцитарного фактора роста человека (pdgf-bb) и способ получения тромбоцитарного фактора роста человека
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
CA2619577A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CN101243190B (zh) 2005-08-16 2015-05-13 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
PT1926749E (pt) * 2005-09-14 2011-09-29 Sanofi Aventis Deutschland Clivagem de precursores de insulinas por uma variante de tripsina
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
ES2541302T3 (es) 2005-11-18 2015-07-17 Glenmark Pharmaceuticals S.A. Anticuerpos anti-integrina alfa2 y sus usos
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2389946A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP2009536022A (ja) 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2044111B1 (de) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting des komplement-faktors h zur krankheitsbehandlung
AU2007276294B2 (en) 2006-06-30 2012-11-29 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
HRP20140081T1 (hr) 2006-08-18 2014-03-28 Novartis Ag Prlr-specifiäśna antitijela i njihova uporaba
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
CN101687031B (zh) 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
KR101581279B1 (ko) 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
EP2121743B1 (de) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Gezielte therapeutika auf der basis von manipulierten proteinen für tyrosinkinaserezeptoren, einschliesslich igf-ir
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
CA2672120A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
MX2009007632A (es) 2007-01-22 2009-07-24 Genentech Inc Precipitacion de polielectrolito y purificacion de proteinas.
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
CA2887752C (en) * 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2008150841A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
KR20150029002A (ko) 2007-06-07 2015-03-17 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
BRPI0820343A2 (pt) 2007-11-08 2017-08-22 Genentech Inc Anticorpos de antifator b e seus usos
CN104059143A (zh) 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
US9200270B2 (en) 2008-03-03 2015-12-01 Abbvie Inc. Methods for transforming yeast
WO2009114560A2 (en) 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
SG190596A1 (en) 2008-05-06 2013-06-28 Genentech Inc Affinity matured crig variants
CN102112147B (zh) 2008-06-02 2014-05-21 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138、和cs1肽
CN102149724B (zh) 2008-08-14 2014-04-09 健泰科生物技术公司 使用原地蛋白质置换离子交换膜层析清除污染物的方法
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
TWI610936B (zh) 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
SG195557A1 (en) 2008-10-22 2013-12-30 Genentech Inc Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EP2346903A1 (de) 2008-11-06 2011-07-27 Glenmark Pharmaceuticals S.A. Behandlung mit anti-alpha2-integrinantikörpern
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
KR20120057565A (ko) 2009-04-01 2012-06-05 제넨테크, 인크. 항-ＦｃＲＨ５ 항체 및 면역접합체 및 사용 방법
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
WO2010124163A2 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
JP5805634B2 (ja) 2009-06-08 2015-11-04 アムニクス オペレーティング インコーポレイテッド 成長ホルモンポリペプチド並びにその作成及び使用方法
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
JP2012533306A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ 機械的伝達による細胞産生の強化
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
KR101764449B1 (ko) 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
EP2473522B1 (de) 2009-09-02 2016-08-17 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CN102712914A (zh) 2009-09-29 2012-10-03 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
EP3037104B1 (de) 2009-10-20 2020-05-27 AbbVie Inc. Isolation und aufreinigung von anti-il-13-antikörpern mittels protein-a-affinitätschromatografie
MX2012004638A (es) 2009-10-22 2012-07-04 Genentech Inc Modulacion de degeneracion de axones.
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
DK2501805T3 (en) 2009-11-19 2019-04-15 Oxyrane Uk Ltd Yeast strains producing mammalian-like complex N-Glycans
TWI537383B (zh) 2009-11-30 2016-06-11 建南德克公司 診斷及治療腫瘤之組合物及方法
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
EP2509626B1 (de) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
DK2513135T3 (da) 2009-12-18 2020-05-18 Csl Ltd Fremgangsmåde til oprensning af polypeptider
EP2515932A2 (de) 2009-12-21 2012-10-31 Centre Hospitalier Universitaire Vaudois (CHUV) Synergetische wirkung einer prolylprotease und tripeptidylproteasen
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
US8940303B2 (en) 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR101712820B1 (ko) 2010-02-23 2017-03-22 사노피 항-알파2 인테그린 항체 및 그 용도
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
PT3178851T (pt) 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
PL2576580T3 (pl) 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
JP2013534515A (ja) 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
CA2800206C (en) 2010-06-25 2018-06-05 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of respiratory tract infections
CA2805035A1 (en) 2010-07-22 2012-01-26 Glaxosmithkline Biologicals S.A. Novel antigen binding proteins
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
US8900590B2 (en) 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
EP4549461A3 (de) 2010-08-31 2025-08-06 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
JP2014506115A (ja) 2010-09-15 2014-03-13 アリグナ テクノロジーズ，インク． リグニン由来の化合物からの芳香族化学物質のバイオプロダクション
CA2810909A1 (en) 2010-09-20 2012-03-29 Abbvie Inc. Purification of antibodies using simulated moving bed chromatography
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
WO2012042387A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
EP2625197B1 (de) 2010-10-05 2016-06-29 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
KR101571940B1 (ko) 2010-10-08 2015-11-25 상하이 켁신 바이오테크 씨오., 엘티디. 면역성 혈소판 감소증과 관련된 모에신 단편
KR101708533B1 (ko) 2010-10-08 2017-02-20 상하이 켁신 바이오테크 씨오., 엘티디. 재생불량 빈혈과 관련된 모에신 단편
US9345765B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
KR101641756B1 (ko) 2010-10-08 2016-07-21 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 단편 및 그의 용도
US9345764B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
EP2635674A4 (de) 2010-11-05 2014-11-05 Transbio Ltd Marker für endothelial-vorläuferzellen und verwendungen davon
SG190129A1 (en) 2010-11-05 2013-06-28 Abbvie Inc Efficient and effective supplement screening for the development of chemically defined media in cell culture
WO2012064619A1 (en) * 2010-11-10 2012-05-18 Merck Sharp & Dohme Corp. Pichia pastoris loci encoding enzymes in the proline biosynthetic pathway
EP2640831A1 (de) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
JP6147670B2 (ja) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
CA2827301A1 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
US20120315277A1 (en) 2011-03-15 2012-12-13 Theraclone Sciences, Inc. Compositions and Methods for the Therapy and Diagnosis of Influenza
WO2012128810A1 (en) 2011-03-23 2012-09-27 Abbott Laboratories Methods and systems for the analysis of protein samples
EP3412309A1 (de) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Verfahren zur verabreichung von beta7-integrin-antagonisten
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3954704A1 (de) 2011-06-03 2022-02-16 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
EP2731677B1 (de) 2011-07-11 2018-04-18 Glenmark Pharmaceuticals S.A. An ox40 bindende antikörper und ihre verwendungen
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
EP2758438A1 (de) 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispezifische bindende moleküle für 5t4 und cd3
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
FI3536710T3 (fi) 2011-11-16 2026-01-14 Boehringer Ingelheim Int Anti-il-36r -vasta-aineita
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN104471068A (zh) 2011-12-16 2015-03-25 布拉斯科南美公司(巴西) 经修饰的微生物和使用其制造丁二烯的方法
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
EP2798074A1 (de) 2011-12-30 2014-11-05 Oxyrane UK Limited Verfahren und materialien zur reduktion der degradation von rekombinanten proteinen
CA2860782A1 (en) 2012-01-19 2013-07-25 Patrick Tso Method of treating diabetes using non-glycosylated apolipoprotein a-iv
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
MX353382B (es) 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
EP3628326B1 (de) 2012-03-15 2024-02-28 Oxyrane UK Limited Verfahren und materialien zur behandlung von morbus pompe
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
ES2648487T3 (es) 2012-04-27 2018-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antagonistas de factor de crecimiento endotelial vascular y métodos para su uso
NZ700802A (en) 2012-05-03 2017-06-30 Boehringer Ingelheim Int Anti-il-23p19 antibodies
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
AU2013337247B2 (en) 2012-11-05 2018-08-09 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
JP2016503818A (ja) 2013-01-02 2016-02-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｌ１ａと結合する抗体およびその使用
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
EP2964758B1 (de) 2013-03-05 2020-05-27 Oxyrane UK Limited Herstellung von katalytisch aktiver typ-i-sulfatase
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
MY199135A (en) 2013-03-13 2023-10-17 Genentech Inc Formulations with reduced oxidation
CA2904169C (en) 2013-03-13 2021-12-07 Genentech, Inc. Formulations with reduced oxidation
AU2013384204B2 (en) 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
HK1213919A1 (zh) 2013-03-14 2016-07-15 Abbvie Inc. 低酸性物質組合物和利用置換色譜技術製備該組合物的方法
US20140271633A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Mammalian cell culture performance through surfactant supplementation of feed media
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
EP2968495B1 (de) 2013-03-15 2019-07-03 Daniel J. Capon Hybrides immunglobulin mit nichtpeptidylverbindung
HK1213179A1 (zh) 2013-03-15 2016-06-30 豪夫迈‧罗氏有限公司 细胞培养培养基和抗体生产方法
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
SI2970449T1 (sl) 2013-03-15 2019-11-29 Amgen Res Munich Gmbh Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
BR112015021993A8 (pt) 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
EP2976362B1 (de) 2013-03-19 2019-10-23 Beijing Shenogen Pharma Group Ltd. Antikörper und verfahren zur behandlung von östrogenrezeptor-assoziierten erkrankungen
CA2904095A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CA2910029A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
WO2015069459A1 (en) 2013-11-05 2015-05-14 Novartis Ag Organic compounds
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
CN106062005A (zh) 2013-12-30 2016-10-26 医药生命融合研究团 抗krs单克隆抗体及其用途
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
ES2788973T3 (es) 2014-03-14 2020-10-23 Biomolecular Holdings Llc Inmunoglobulina híbrida que contiene una unión distinta de peptidilo
SG11201607929PA (en) 2014-03-25 2016-10-28 Genentech Inc Methods of preparing a poloxamer for use in cell culture medium
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
EP3149187B1 (de) 2014-05-30 2020-04-29 Braskem S.A. Modifizierte mikroorganismen mit einem optimierten system zur oligosaccharidnutzung und verfahren zur verwendung davon
EP3145951A1 (de) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Verfahren zur reinigung von antikörpern
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
MX384418B (es) 2014-07-31 2025-03-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
MX2017007055A (es) 2014-12-03 2017-11-08 Genentech Inc Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
WO2016120764A1 (en) 2015-01-26 2016-08-04 Centre Hospitalier Universitaire Vaudois (Chuv) Aspergillus oryzae prolyl endopeptidases and use thereof in degradation of polypeptides
IL321788A (en) 2015-02-04 2025-08-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
CA2972099A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
EP3391905A1 (de) 2015-04-14 2018-10-24 Boehringer Ingelheim International GmbH Behandlung von asthma mittels antikörper gegen il-23a
TWI772258B (zh) 2015-04-17 2022-08-01 德商安美基研究（慕尼黑）公司 Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
MX388405B (es) 2015-05-29 2025-03-19 Genentech Inc Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MY187739A (en) 2015-08-11 2021-10-18 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
WO2017042242A1 (en) 2015-09-07 2017-03-16 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Novel igfr-like receptor and uses thereof
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2017109034A1 (en) 2015-12-24 2017-06-29 Oxyrane Uk Ltd Human alpha-n-acetylgalactosaminidase polypeptide
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
EP3397243A1 (de) 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Verwendung von tryptophanderivaten für proteinformulierungen
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
MX2018010546A (es) 2016-03-15 2019-02-20 Chugai Pharmaceutical Co Ltd Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
EP3433277A4 (de) 2016-03-23 2020-06-17 Mabspace Biosciences (Suzhou) Co., Ltd Neuartige anti-pd-l1-antikörper
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
US20170298126A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EP3464354B1 (de) 2016-06-02 2021-07-28 Bloom Diagnostics AG Antikörper zur bindung an humane anti-müller-hormone (amh) und deren verwendungen
EP3490600A1 (de) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
US11111313B2 (en) 2016-09-20 2021-09-07 WuXi Biologics Ireland Limited Anti-PCSK9 antibodies
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3848390A1 (de) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Verfahren zur behandlung von krankheiten
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
EP3574007A1 (de) 2017-01-30 2019-12-04 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Neuartiger igfr-like-2-rezeptor und verwendungen davon
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3596126A4 (de) 2017-03-15 2021-03-03 Tsinghua University Neuartige anti-trkb-antikörper
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
WO2018182284A1 (ko) 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
AU2018261951B2 (en) 2017-05-05 2025-05-22 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
CN111094334A (zh) 2017-07-19 2020-05-01 美国卫生与公众服务部 用于诊断和治疗乙肝病毒感染的抗体和方法
CA3070468A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
KR20250029294A (ko) 2017-09-22 2025-03-04 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
WO2019089544A1 (en) 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
TWI827570B (zh) 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US11401336B2 (en) 2018-02-21 2022-08-02 Celgene Corporation BCMA-binding antibodies and uses thereof
US12202894B2 (en) 2018-03-20 2025-01-21 WuXi Biologics Ireland Limited Anti-TIM-3 antibodies
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
CN112334485B (zh) 2018-04-06 2024-09-27 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP7504808B2 (ja) 2018-06-29 2024-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫疾患の処置における使用のための抗ｃｄ４０抗体
IL280525B2 (en) 2018-08-08 2024-11-01 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
EP3856343A1 (de) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
BR112021005669A2 (pt) 2018-09-28 2021-06-22 Amgen Inc. anticorpos contra bcma solúvel
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
US20210388108A1 (en) 2018-10-23 2021-12-16 Glycardial Diagnostics, S.L. Antibodies specific for glycosylated apoj and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
JP7607579B2 (ja) 2019-03-27 2024-12-27 ティガティーエックス， インコーポレイテッド 工学的に操作されたＩｇＡ抗体および使用方法
MY206253A (en) 2019-05-09 2024-12-05 Boehringer Ingelheim Int Anti-sema3a antibodies and their uses for treating eye or ocular diseases
KR20220012262A (ko) 2019-05-24 2022-02-03 산유 바이오파마슈티컬스 씨오., 엘티디. 신형 cldn18.2 결합분자
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
KR102442204B1 (ko) 2019-09-20 2022-09-08 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
EP4058485A1 (de) 2019-11-13 2022-09-21 Amgen Inc. Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
KR20220152316A (ko) 2020-03-12 2022-11-15 이뮨-온크 테라퓨틱스, 인코포레이티드 신규한 항-lilrb4 항체 및 유도체 생성물
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
US20210371809A1 (en) 2020-04-15 2021-12-02 Genentech, Inc. Copper loss mitigation
EP4153633A1 (de) 2020-05-19 2023-03-29 Amgen Inc. Mageb2-bindende konstrukte
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
EP4165076A1 (de) 2020-06-15 2023-04-19 Sarepta Therapeutics, Inc. Adeno-assoziierte virusantikörper und fragmente davon
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
EP3939999A1 (de) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Antikörper zur neutralisierung der interleukin-11-rezeptor-alpha-unterheinheit (il11ra) und verwendungen davon
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
EP4240767A1 (de) 2020-11-06 2023-09-13 Amgen Inc. An cd3 bindende polypeptidkonstrukte
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
MX2023005197A (es) 2020-11-06 2023-05-16 Amgen Inc Dominio de union a antigeno con tasa de recorte reducida.
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
CA3202339A1 (en) 2020-12-18 2022-06-23 Mei Jang Protein compositions and methods for producing and using the same
EP4314078A1 (de) 2021-04-02 2024-02-07 Amgen Inc. Mageb2-bindende konstrukte
US20240238431A1 (en) 2021-04-26 2024-07-18 Xuanzhu Biopharmaceutical Co., Ltd. Bispecific Antibody-Drug Conjugate
EP4373855A1 (de) 2021-07-23 2024-05-29 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Igfr-l1-antikörper und verwendungen davon
WO2023105087A1 (en) 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
KR20230098953A (ko) 2021-12-27 2023-07-04 경북대학교 산학협력단 Asm에 특이적으로 결합하는 항체 및 이의 용도
EP4471138A4 (de) 2022-01-29 2026-02-25 Univ Peking First Hospital Iga-protease-verkürzung, fusionsprotein mit iga-protease-verkürzung und verwendung davon
EP4238988A1 (de) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antikörper gegen sars-cov-2 und verwendungen davon
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
WO2024032891A1 (en) 2022-08-11 2024-02-15 Vib Vzw Glyco-engineered yeast for therapeutic protein production
IL319125A (en) 2022-08-22 2025-04-01 Abdera Therapeutics Inc DLL3 binding molecules and their uses
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
AU2023362470A1 (en) 2022-10-18 2025-05-29 Tubulis Gmbh Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2024083925A2 (en) 2022-10-18 2024-04-25 Tubulis Gmbh Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
JP2025542322A (ja) 2022-12-23 2025-12-25 チマゲン・バイオサイエンシズ，リミテッド Ｇｐｒｃ５ｄを標的とする多重特異性ポリペプチド複合物
AU2023412611A1 (en) 2022-12-23 2025-07-10 Chimagen Biosciences, Ltd Novel anti-gprc5d antibody
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
AU2024302269A1 (en) 2023-06-14 2025-11-13 Amgen Inc. T cell engager masking molecules
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025043134A1 (en) 2023-08-24 2025-02-27 Rezolute, Inc. High concentration formulations for anti-insulin receptor antibody and uses thereof
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
WO2025104253A1 (en) 2023-11-17 2025-05-22 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025144974A1 (en) 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism
WO2025212738A1 (en) 2024-04-04 2025-10-09 BioLegend, Inc. Chi3l1 binding antibodies and antigen binding fragments thereof
WO2025230843A2 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Kir binding antibodies and antigen binding fragments thereof
EP4653010A1 (de) 2024-05-14 2025-11-26 35Pharma Inc. Activinrezeptor-typ-iib-varianten und verwendungen davon
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068969B (en) * 1980-02-05 1983-07-27 Upjohn Co Gene expression
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4617274A (en) * 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
IE55817B1 (en) * 1982-05-19 1991-01-30 Gist Brocades Nv Cloning system for kluyveromyces species
NO840200L (no) * 1983-01-28 1984-07-30 Cefus Corp Glukoamylase cdna.
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast

Also Published As

Publication number Publication date
FI854145L (fi) 1986-05-01
EP0183070A2 (de) 1986-06-04
MX430A (es) 1993-11-01
DE3584353D1 (de) 1991-11-14
PT81402B (pt) 1987-11-11
DK496485D0 (da) 1985-10-29
ZA858180B (en) 1986-06-25
NO178975B (no) 1996-04-01
CA1297438C (en) 1992-03-17
DK496485A (da) 1986-05-01
PT81402A (en) 1985-11-01
AU4875685A (en) 1986-06-12
FI94428B (fi) 1995-05-31
NO178975C (no) 1996-07-10
AU572353B2 (en) 1988-05-05
SG43092G (en) 1992-06-12
IE852473L (en) 1986-04-30
NO854334L (no) 1986-05-02
IL76763A0 (en) 1986-02-28
JPS61108383A (ja) 1986-05-27
EP0183070A3 (en) 1987-09-30
US4879231A (en) 1989-11-07
IL76763A (en) 1991-03-10
ES8609464A1 (es) 1986-09-01
FI94428C (fi) 1995-09-11
ES548306A0 (es) 1986-09-01
FI854145A0 (fi) 1985-10-23
EP0183070B1 (de) 1991-10-09
IE58217B1 (en) 1993-08-11
GR852609B (de) 1986-03-04
JPH0681593B2 (ja) 1994-10-19

Similar Documents

Publication Publication Date Title
ATE68204T1 (de) Transformation von hefe des genus pichia.
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
ES518348A0 (es) Un plasmido vector recombinante.
BR8506273A (pt) Gene de glicoamilase,vetor compreendendo o mesmo,microorganismo transformado,e processo para produzir glicoamilase
KR960700346A (ko) 면역억제제의 제조방법 및 이에 사용되는 신규 미생물(a process for producing immunosuppressives and a novel microbial species to be employed therein)
ATE81136T1 (de) Immunogenes produkt, erhalten durch expression in einer rekombinanten hefe, und verfahren zu seiner reinigung.
PT81052B (pt) Processo de preparacao de saccharomyces recombinantes
PT80174A (en) Process for the preparation of n1-methyl-10alpha-methoxylumilysergol and esters thereof and intermediates for their preparation
ES537637A0 (es) Un metodo de producir guanosina
BR8502586A (pt) Processo para preparar uma cepa de b.subtilis
ATE39117T1 (de) Verfahren und zwischenprodukte fuer sorbinil.
CA2002480A1 (en) Process for the production of human lysozyme
JPS645487A (en) Novel microorganism
KR950018453A (ko) 콜라게네이즈 인지부위를 가진 재조합 인간 성장 호르몬

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time